QKI is a vital regulator in RNA splicing and maturation, but its role in cervical cancer (CC) is little known. In this study, we found that QKI is decreased in human CC, and overexpression of QKI inhibits HeLa cell proliferation and promotes the apoptosis of cancer cells. We identified hundreds of endogenous QKI-regulated alternative splicing events (ASEs) and differentially expressed genes (DEGs) in QKI-overexpressed HeLa cells by RNA-seq and selectively validated their expression by quantitative reverse-transcription polymerase chain reaction. The gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis showed that QKI-regulated ASEs and DEGs were closely related to cancer, apoptosis, and transcriptional regulatory functions. In short, QKI may affect the occurrence and development of CC by regulating gene expression through AS.
Get full access to this article
View all access options for this article.
References
1.
ArielF., and CrespiM. (2017). Alternative splicing: the lord of the rings. Nat Plants 3,17065.
2.
AzamS.H., PorrelloA., HarrisonE.B., LeslieP.L., LiuX., WaughT.A., et al. (2019). Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene, 38, 5191–5210.
3.
BaralleF.E., and GiudiceJ. (2017). Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol, 18, 437–451.
4.
BemJ., BrożkoN., ChakrabortyC., LipiecM.A., KozińskiK., NagalskiA., et al. (2019). Wnt/β-catenin signaling in brain development and mental disorders: keeping TCF7L2 in mind. FEBS Lett, 593, 1654–1674.
5.
BianY., WangL., LuH., YangG., ZhangZ., FuH., et al. (2012). Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. Biochem Biophys Res Commun, 422, 187–193.
6.
BiedermannB., HotzH.R., and CioskR. (2010). The Quaking family of RNA-binding proteins: coordinators of the cell cycle and differentiation. Cell Cycle, 9, 1929–1933.
7.
BlencoweB.J. (2017). The relationship between alternative splicing and proteomic complexity. Trends Biochem Sci, 42, 407–408.
8.
BouilletP., PurtonJ.F., GodfreyD.I., ZhangL.C., CoultasL., PuthalakathH., et al. (2002). BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature, 415, 922–926.
9.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
10.
BusseT.M., RothJ.J., WilmothD., WainwrightL., TookeL., and BiegelJ.A. (2017). Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients. Genes Chromosomes Cancer, 56, 730–749.
11.
ChenX., LiX., WangX., ZhuQ., WuX., and WangX. (2019). MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research. BMC Cancer 19,171.
12.
CheungJ.L., CheungT.H., YuM.Y., YeungA.C., and ChanP.K. (2014). Selection of referent transcript for normalization of gene expression in cervical cytology samples. Appl Immunohistochem Mol Morphol, 22, 153–157.
13.
Córdova-AlarcónE., CentenoF., Reyes-EsparzaJ., García-CarrancáA., and GarridoE. (2005). Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch Med Res, 36, 311–316.
14.
DarbelliL., and RichardS. (2016). Emerging functions of the Quaking RNA-binding proteins and link to human diseases. Wiley Interdiscip Rev RNA, 7, 399–412.
15.
de CamposR.P., SchultzI.C., de Andrade MelloP., DaviesS., GasparinM.S., BertoniA., et al. (2018). Cervical cancer stem-like cells: systematic review and identification of reference genes for gene expression. Cell Biol Int, 42, 139–152.
16.
de MiguelF.J., PajaresM.J., Martínez-TerrobaE., AjonaD., MoralesX., SharmaR.D., et al. (2016). A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer. Mol Oncol, 10, 1437–1449.
17.
DijkersP.F., BirkenkampK.U., LamE.W., ThomasN.S., LammersJ.W., KoendermanL., et al. (2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol, 156, 531–542.
18.
DongreA., and WeinbergR.A. (2019). New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol, 20, 69–84.
19.
FanK., YangC., FanZ., HuangQ., ZhangY., ChengH., et al. (2018). MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Cancer Lett, 418, 167–175.
20.
FelderM., KapurA., Gonzalez-BosquetJ., HoribataS., HeintzJ., AlbrechtR., et al. (2014). MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 13,129.
21.
FuX., and FengY. (2015). QKI-5 suppresses cyclin D1 expression and proliferation of oral squamous cell carcinoma cells via MAPK signalling pathway. Int J Oral Maxillofac Surg, 44, 562–567.
22.
GalarneauA., and RichardS. (2005). Target RNA motif and target mRNAs of the Quaking STAR protein. Nat Struct Mol Biol, 12, 691–698.
23.
GaoY., WangJ., ZhouY., ShengS., QianS.Y., and HuoX. (2018). Evaluation of Serum CEA, CA19–9, CA72–4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep 8,2732.
24.
GinsburgO., BrayF., ColemanM.P., VanderpuyeV., EniuA., KothaS.R., et al. (2017). The global burden of women's cancers: a grand challenge in global health. Lancet, 389, 847–860.
25.
GonzalezD.M., and MediciD. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 7,re8.
26.
GuptaS., MaheshwariA., ParabP., MahantshettyU., HawaldarR., Sastri ChopraS., et al. (2018). Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol, 36, 1548–1555.
27.
HeB., GaoS.Q., HuangL.D., HuangY.H., ZhangQ.Y., ZhouM.T., et al. (2015). MicroRNA-155 promotes the proliferation and invasion abilities of colon cancer cells by targeting quaking. Mol Med Rep, 11, 2355–2359.
28.
HeH., SongF., GaoQ., LuZ., YuanY., LiX., et al. (2021). The APEX1/miRNA-27a-5p axis plays key roles in progression, metastasis and targeted chemotherapy of gastric cancer. Int J Pharm 599,120446.
29.
HowardJ.M., and SanfordJ.R. (2015). The RNAissance family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip Rev RNA, 6, 93–110.
30.
IkedaS., KagamiT., TaniS., UotaniT., YamadeM., HamayaY., et al. (2019). Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report. BMC Gastroenterol 19,141.
31.
Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, F., Sun, N., Bantis, L.E., Muller, D.C., Li, P., et al. (2018). Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins. JAMA Oncol 4, e182078.
32.
IwataN., IshikawaT., OkazakiS., MogushiK., BabaH., IshiguroM., et al. (2017). Clinical significance of methylation and reduced expression of the quaking gene in colorectal cancer. Anticancer Res, 37, 489–498.
33.
JiS., YeG., ZhangJ., WangL., WangT., WangZ., et al. (2013). miR-574-5p negatively regulates Qki6/7 to impact β-catenin/Wnt signalling and the development of colorectal cancer. Gut, 62, 716–726.
34.
JinL., LiG., YuD., HuangW., ChengC., LiaoS., et al. (2017). Transcriptome analysis reveals the complexity of alternative splicing regulation in the fungus Verticillium dahliae. BMC Genomics 18,130.
35.
KalogeropoulouM., VoulgariA., KostourouV., SandaltzopoulosR., DiksteinR., DavidsonI., et al. (2010). TAF4b and Jun/activating protein-1 collaborate to regulate the expression of integrin alpha6 and cancer cell migration properties. Mol Cancer Res, 8, 554–568.
36.
KimB.W., ChoH., YlayaK., KitanoH., ChungJ.Y., HewittS.M., et al. (2017). Bcl-2-like Protein 11 (BIM) expression is associated with favorable prognosis for patients with cervical cancer. Anticancer Res, 37, 4873–4879.
37.
KimD., PerteaG., TrapnellC., PimentelH., KelleyR., and SalzbergS.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14,R36.
38.
KimE.J., KimJ.S., LeeS., LeeH., YoonJ.S., HongJ.H., et al. (2019). QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth. Int J Cancer, 145, 1585–1595.
39.
KimJ.S., KuB., WooT.G., OhA.Y., JungY.S., SohY.M., et al. (2015). Conversion of cell-survival activity of Akt into apoptotic death of cancer cells by two mutations on the BIM BH3 domain. Cell Death Dis 6,e1804.
40.
KędzierskaH., and Piekiełko-WitkowskaA. (2017). Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett, 396, 53–65.
41.
LeiteK.R., MoraisD.R., ReisS.T., VianaN., MouraC., FlorezM.G., et al. (2013). MicroRNA 100: a context dependent miRNA in prostate cancer. Clinics (Sao Paulo), 68, 797–802.
42.
LeiteK.R., Sousa-CanavezJ.M., ReisS.T., TomiyamaA.H., Camara-LopesL.H., SañudoA., et al. (2011). Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol, 29, 265–269.
43.
LiB., LiX., XiongH., ZhouP., NiZ., YangT., et al. (2017). Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells. Oncotarget, 8, 51748–51757.
44.
LiF., YiP., PiJ., LiL., HuiJ., WangF., et al. (2016a). QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis. Oncotarget, 7, 32821–32834.
45.
LiH., WuX., and ChengX. (2016b). Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27,e43.
46.
LiL., YangW.T., ZhengP.S., and LiuX.F. (2018). SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer. Cell Death Dis 9,741.
47.
LiX., DaiD., ChenB., HeS., ZhangJ., WenC., et al. (2019). Prognostic values of preoperative serum CEA And CA125 levels and nomograms for young breast cancer patients. Onco Targets Ther, 12, 8789–8800.
48.
LiuF., DaiM., XuQ., ZhuX., ZhouY., JiangS., et al. (2018a). SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. Oncogene, 37, 2394–2409.
49.
LiuQ., OsterlundE.J., ChiX., PogmoreJ., LeberB., and AndrewsD.W. (2019). Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. Elife 8,e37689.
50.
LiuX., ZhangY., WangY., BianC., and WangF. (2020). Long non-coding RNA KCNQ1OT1 up-regulates CTNND1 by sponging miR-329-3p to induce the proliferation, migration, invasion, and inhibit apoptosis of colorectal cancer cells. Cancer Cell Int 20,340.
51.
LiuX.F., LiX.Y., ZhengP.S., and YangW.T. (2018b). DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β. Cell Death Dis 9,339.
52.
LiuY., Gonzàlez-PortaM., SantosS., BrazmaA., MarioniJ.C., AebersoldR., et al. (2017). Impact of alternative splicing on the human proteome. Cell Rep, 20, 1229–1241.
53.
LivakK.J., and SchmittgenT.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402–408.
54.
MaffeisV., NicolèL., and CappellessoR. (2019). RAS, cellular plasticity, and tumor budding in colorectal cancer. Front Oncol 9,1255.
55.
Martinez-MontielN., Rosas-MurrietaN.H., Anaya RuizM., Monjaraz-GuzmanE., and Martinez-ContrerasR. (2018). Alternative splicing as a target for cancer treatment. Int J Mol Sci 19,545.
56.
MasoudG.N., and LiW. (2015). HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B, 5, 378–389.
57.
MengX., YangS., and CampV. (2019). The interplay between the DNA damage response, RNA processing and extracellular vesicles. Front Oncol 9,1538.
58.
MoraisD.R., ReisS.T., VianaN., PiantinoC.B., MassocoC., MouraC., et al. (2014). The involvement of miR-100 in bladder urothelial carcinogenesis changing the expression levels of mRNA and proteins of genes related to cell proliferation, survival, apoptosis and chromosomal stability. Cancer Cell Int 14,119.
59.
NakkaK., GhignaC., GabelliniD., and DilworthF.J. (2018). Diversification of the muscle proteome through alternative splicing. Skelet Muscle 8,8.
60.
NemajerovaA., and MollU.M. (2019). Tissue-specific roles of p73 in development and homeostasis. J Cell Sci 132,jcs233338.
61.
NiloffJ.M., KlugT.L., SchaetzlE., ZurawskiV.R.Jr, KnappR.C., and BastR.C. Jr. (1984). Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol, 148, 1057–1058.
62.
PandeyS., MaharanaJ., LiX.X., WoodruffT.M., and ShuklaA.K. (2020). Emerging insights into the structure and function of complement C5a receptors. Trends Biochem Sci, 45, 693–705.
63.
ParonettoM.P., PassacantilliI., and SetteC. (2016). Alternative splicing and cell survival: from tissue homeostasis to disease. Cell Death Differ, 23, 1919–1929.
64.
PlanellsB., Gómez-RedondoI., PericuestaE., LonerganP., and Gutiérrez-AdánA. (2019). Differential isoform expression and alternative splicing in sex determination in mice. BMC Genomics 20,202.
65.
RobinsonM.D., McCarthyD.J., and SmythG.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26, 139–140.
66.
RumpA., MorikawaY., TanakaM., MinamiS., UmesakiN., TakeuchiM., et al. (2004). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem, 279, 9190–9198.
67.
ShiF., DengZ., ZhouZ., JiangC.Y., ZhaoR.Z., SunF., et al. (2019). QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-κB signalling. J Cell Mol Med, 23, 6578–6594.
68.
ShiF., WeiD., ZhuZ., YanF., WangF., ZhangK., et al. (2020). The RNA-binding protein QKI suppresses tumorigenesis of clear cell renal cell carcinoma by regulating the expression of HIF-1α. J Cancer, 11, 1359–1370.
69.
ShinguT., HoA.L., YuanL., ZhouX., DaiC., ZhengS., et al. (2017). Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet, 49, 75–86.
70.
ShkretaL., ToutantJ., DurandM., ManleyJ.L., and ChabotB. (2016). SRSF10 connects DNA damage to the alternative splicing of transcripts encoding apoptosis, cell-cycle control, and DNA repair factors. Cell Rep, 17, 1990–2003.
71.
SubasicD., StoegerT., EisenringS., Matia-GonzálezA.M., ImigJ., ZhengX., et al. (2016). Post-transcriptional control of executioner caspases by RNA-binding proteins. Genes Dev, 30, 2213–2225.
72.
SultanM., SchulzM.H., RichardH., MagenA., KlingenhoffA., ScherfM., et al. (2008). A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science, 321, 956–960.
73.
SzegezdiE., HerbertK.R., KavanaghE.T., SamaliA., and GormanA.M. (2008). Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion via regulation of Bim. J Cell Mol Med, 12, 2482–2496.
74.
TongR., ZhangJ., WangC., LiQ., WangL., and JuM. (2020). Inhibition of miR-574-5p suppresses cell growth and metastasis and enhances chemosensitivity by targeting RNA binding protein QKI in cervical cancer cells. Naunyn Schmiedebergs Arch Pharmacol, 393, 951–966.
75.
TrapnellC., WilliamsB.A., PerteaG., MortazaviA., KwanG., van BarenM.J., et al. (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol, 28, 511–515.
76.
UntchB.R., Dos AnjosV., Garcia-RenduelesM., KnaufJ.A., KrishnamoorthyG.P., SaqcenaM., et al. (2018). Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers. Cancer Res, 78, 4642–4657.
77.
WangB., WangM., LiX., YangM., and LiuL. (2020a). Variations in the Wnt/β-catenin pathway key genes as predictors of cervical cancer susceptibility. Pharmgenomics Pers Med, 13, 157–165.
78.
WangH., YanC., and YeH. (2020b). Overexpression of MUC16 predicts favourable prognosis in MUC16-mutant cervical cancer related to immune response. Exp Ther Med, 20, 1725–1733.
79.
WangJ.D., KatzS.G., MorganE.A., YangD.T., PanX., and XuM.L. (2019b). Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Hum Pathol, 93, 54–64.
80.
WangX., and XiaY. (2016). microRNA-328 inhibits cervical cancer cell proliferation and tumorigenesis by targeting TCF7L2. Biochem Biophys Res Commun, 475, 169–175.
81.
WangX., YinH., ZhangL., ZhengD., YangY., ZhangJ., et al. (2019a). The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer. J Thorac Dis, 11, 1772–1778.
82.
WardP.A. (2008). Sepsis, apoptosis and complement. Biochem Pharmacol, 76, 1383–1388.
83.
WatersA.M., and DerC.J. (2018). KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med 8,a031435.
84.
WenzelJ., RoseK., HaghighiE.B., LamprechtC., RauenG., FreihenV., et al. (2020). Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells. Oncogene, 39, 3893–3909.
85.
WestcottP.M., HalliwillK.D., ToM.D., RashidM., RustA.G., KeaneT.M., et al. (2015). The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature, 517, 489–492.
86.
WuM., HuangY., ChenT., WangW., YangS., YeZ., et al. (2019). LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med, 23, 29–38.
87.
XiaH., ChenD., WuQ., WuG., ZhouY., ZhangY., et al. (2017). CELF1 preferentially binds to exon-intron boundary and regulates alternative splicing in HeLa cells. Biochim Biophys Acta Gene Regul Mech, 1860, 911–921.
88.
XieC., MaoX., HuangJ., DingY., WuJ., DongS., et al. (2011). KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res, 39, W316–W322.
89.
YamagishiR., TsusakaT., MitsunagaH., MaehataT., and HoshinoS. (2016). The STAR protein QKI-7 recruits PAPD4 to regulate post-transcriptional polyadenylation of target mRNAs. Nucleic Acids Res, 44, 2475–2490.
90.
YangG., FuH., ZhangJ., LuX., YuF., JinL., et al. (2010). RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology, 138, 231–240.e1–e5.
91.
YangG., LuX., WangL., BianY., FuH., WeiM., et al. (2011). E2F1 and RNA binding protein QKI comprise a negative feedback in the cell cycle regulation. Cell Cycle, 10, 2703–2713.
92.
YangY., ParkJ.W., BebeeT.W., WarzechaC.C., GuoY., ShangX., et al. (2016). Determination of a comprehensive alternative splicing regulatory network and combinatorial regulation by key factors during the epithelial-to-mesenchymal transition. Mol Cell Biol, 36, 1704–1719.
93.
YouX., KongG., RanheimE.A., YangD., ZhouY., and ZhangJ. (2018). Unique dependence on Sos1 in Kras G12D -induced leukemogenesis. Blood, 132, 2575–2579.
94.
YuS., GautamN., QuanM., and GaoY. (2019). RSRC1 suppresses gastric cancer cell proliferation and migration by regulating PTEN expression. Mol Med Rep, 20, 1747–1753.
95.
ZhangR.L., YangJ.P., PengL.X., ZhengL.S., XieP., WangM.Y., et al. (2016). RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA. Cell Cycle, 15, 3094–3104.
96.
ZhangX., and ZhangY. (2015). Bladder cancer and genetic mutations. Cell Biochem Biophys, 73, 65–69.
97.
ZhangY., and FengY. (2001). Distinct molecular mechanisms lead to diminished myelin basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in qk(v) dysmyelination. J Neurochem, 77, 165–172.
98.
ZhaoJ.H., LuoY., JiangY.G., HeD.L., and WuC.T. (2011). Knockdown of β-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Invest, 29, 377–382.
99.
ZhouC., TanD.M., ChenL., XuX.Y., SunC.C., ZongL.J., et al. (2017). Effect of miR-212 targeting TCF7L2 on the proliferation and metastasis of cervical cancer. Eur Rev Med Pharmacol Sci, 21, 219–226.
100.
ZhouX., LiX., ChengY., WuW., XieZ., XiQ., et al. (2014). BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun 5,4581.
101.
ZongF.Y., FuX., WeiW.J., LuoY.G., HeinerM., CaoL.J., et al. (2014). The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet 10,e1004289.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
